The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Drug Eluting Stent Market At The End Of The 2026–2030 Forecast Period?
The drug eluting stent market has shown substantial growth in recent years. It is forecast to increase from $8.26 billion in 2025 to $8.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This market’s historical development can be attributed to the rising prevalence of coronary artery disease, the increase in percutaneous coronary intervention procedures, a growing incidence of lifestyle-related cardiovascular conditions, the expansion of cardiac catheterization laboratories, and superior clinical outcomes compared to bare-metal stents.
The drug eluting stent market size is projected to experience substantial expansion over the coming years. This market is set to reach $11.7 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. Factors contributing to this anticipated growth during the forecast period encompass an expanding elderly demographic, a heightened need for less invasive cardiac procedures, increasing understanding of sophisticated stent innovations, the proliferation of specialized cardiac centers, and greater healthcare spending on heart-related conditions. Key developments anticipated in the forecast period include a rise in the uptake of biodegradable polymer stents, an increasing preference for polymer-free drug-eluting stents, wider application in intricate coronary interventions, a move towards preventing long-term restenosis, and a greater need for enhanced drug release management.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp
What Primary Drivers Are Shaping The Development Of The Drug Eluting Stent Market?
The increasing incidence of coronary heart disease is anticipated to drive the expansion of the drug-eluting stent market in the coming years. Coronary heart disease (CHD) is characterized by the narrowing or obstruction of coronary arteries due to plaque accumulation, which can result in serious issues like heart attacks or angina. This condition is on the rise, primarily influenced by inactive lifestyles, unhealthy eating habits, an aging global demographic, and increased detection rates. Drug-eluting stents (DES) offer advantages in managing coronary heart disease by efficiently widening constricted or blocked coronary arteries and releasing drugs to inhibit the re-narrowing (restenosis) of the artery. As an illustration, the National Center for Biotechnology Information, a US government agency, indicated in August 2025 that cardiovascular disease is forecast to grow substantially between 2025 and 2050. This includes a projected 90.0% increase in prevalence, a 73.4% rise in crude mortality, and a 54.7% surge in crude DALYs, culminating in an estimated 35.6 million cardiovascular deaths by 2050, an increase from 20.5 million in 2025. This escalating burden of coronary heart disease is therefore expected to significantly boost the growth of the drug-eluting stent market.
What Segment Types Make Up The Drug Eluting Stent Market?
The drug eluting stent market covered in this report is segmented –
1) By Product: Polymer-Based, Polymer-Free
2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
4) By Application: Coronary Diseases, Peripheral Vascular Diseases
5) By End-User: Hospitals, Specialty Clinics
Subsegments:
1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents
2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents
Which Market Trends Are Creating New Opportunities In The Drug Eluting Stent Market?
Leading firms in the drug eluting stent market are prioritizing the creation of advanced products, like stents with low profiles and high flexibility, aiming to boost their navigability in intricate coronary structures and better patient results. Specifically, a low-profile, high-flexibility stent is a drug eluting stent engineered with a smaller cross-sectional area and increased pliability, enabling smoother passage through constricted, winding, or hardened coronary arteries while ensuring consistent drug release to avert re-narrowing. An example of this is the launch of the XIENCE Sierra Everolimus Eluting Coronary Stent System in India by Abbott Laboratories, a U.S.-based global healthcare company, in May 2024. The XIENCE Sierra boasts an innovative stent architecture, providing superior deliverability with a substantially lower crossing force compared to its rivals. Furthermore, it incorporates a thinner balloon and a refined MULTI LINK structure for improved flexibility, along with robust longitudinal strength that guarantees scaffold integrity and resilience against distortion. Moreover, its broad expansion capabilities facilitate accurate treatment even when vessel diameters fluctuate significantly across a lesion, empowering interventional cardiologists to manage intricate, calcified, or hard-to-access lesions with enhanced accuracy and safety.
Who Are The Key Players Driving Competition In The Drug Eluting Stent Market?
Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation
Read the full drug eluting stent market report here:
https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report
How Does The Drug Eluting Stent Market Perform Across Major Global Regions?
North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Drug Eluting Stent Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp
Browse Through More Reports Similar to the Global Drug Eluting Stent Market 2026, By The Business Research Company
Vascular Stent Market Report 2026
https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report
Bioabsorbable Stents Market Report 2026
https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report
Self Expanding Stents Market Report 2026
https://www.thebusinessresearchcompany.com/report/self-expanding-stents-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model